RxDoctor Payments Data

Kristina Karapetyan, PA

Physician Assistant · Burbank, CANPI 1598829434

Payments from drug & device makers

$3,134in general payments, 2019–2025

Across 137 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$726
  • Shield Therapeutics Inc$431
  • Novartis$210
  • Amgen$192
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$177
  • AstraZeneca$165
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,134 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$226
Medicare patients
17
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate70$83,457
JardianceEmpagliflozin115$74,053
LinzessLinaclotide111$58,342
OzempicSemaglutide61$55,072
JanuviaSitagliptin Phosphate79$47,802
CreonLipase/Protease/Amylase41$46,050
VascepaIcosapent Ethyl202$39,202
Metformin Er GastricMetformin Hcl16$34,890
Diclofenac Potassium18$28,068
UbrelvyUbrogepant26$25,445
EliquisApixaban31$25,236
Icosapent Ethyl203$16,193
TradjentaLinagliptin24$12,320
Dexlansoprazole DrDexlansoprazole44$9,700
MyrbetriqMirabegron21$9,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Ubrelvy$726$129,838178 claims
Boehringer IngelheimJardiance, Tradjenta$112$86,373139 claims
Novo NordiskOzempic$13$55,07261 claims
MerckJanuvia, Janumet Xr$93$53,48890 claims
PfizerEliquis$147$25,23631 claims
Scilex Pharmaceuticals Inc.Colchicine$18$1,17227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →